Efficacy of lenalidomide in myelodysplastic syndromes.

By A. List, S. Kurtin, D. Roe, Andrew J. Buresh, D. Mahadevan, D. Fuchs, L. Rimsza, R. Heaton, R. Knight, J. Zeldis. New England Journal of Medicine, 2005

786 citations recorded by the source corpus.

Subfields: Genetics, Hematology

View Paper: https://www.semanticscholar.org/paper/35146dae19b639f1fd5030dcb548076656846f05

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. L. Malcovati
2. E. Hellström-Lindberg
3. D. Bowen
4. J. Schanz
5. L. Adès
6. J. Čermák
7. U. Germing
8. P. Fenaux

Citations in the corpus

• Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. (2006, neutral): “Thalidomide28 83 Low/Int1, 70; High/Int2, 30 13 (5) 0 (1) 0 Thalidomide29 29 RA, 14; RARS, 4; RAEB, 3; RAEB-t, 5; CMML, 3 10 (21) 14 (7) 3 (7) Arsenic trioxide20 101 Low/Int1, 39; High/Int2, 61 11 (0) 6 (0) 8 (0) Valproic acid30 18 Low, 17; Int1, 55; Int2, 17; High, 11 11 (0) 11 (0) 6 (0)”
• New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. (2007, background): “transfusion independence in transfusion-dependent Low/Int-1-risk MDS, with significantly greater response among patients harboring del(5q31).(50,51) Lenalidomide was also associated with a high rate of cytogenetic remission among patients with del(5q31).”
• Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. (2013, background): “List and co-workers treated 43 patients with transfusion-dependent or symptomatic anemia (88% with IPSS risk low or intermediate-1) with lenalidomide, at doses of 25 or 10 mg/day or of 10 mg/day for 21 days of every 28-day cycle.(231) Twenty-four patients had a response and 20 achieved sustained ind”